Freshness note: This analysis was last updated 30 days ago. Fast-moving policy claims can change quickly, so check for newer official updates before relying on this verdict.
“The CDC awarded $1.6 million for a study of birth dose hepatitis B vaccine in Guinea-Bissau that WHO has slammed as 'unethical'”
Summary
The CDC did award approximately $1.6 million for a randomized controlled trial studying hepatitis B vaccine timing in newborns in Guinea-Bissau, scheduled to run through 2026. The WHO Regional Office for Africa issued a statement expressing ethical concerns about the study design, though the characterization of this as being 'slammed' represents editorial framing of institutional criticism.
Primary Sources
CDC funding award details for the Guinea-Bissau hepatitis B vaccine birth dose study
WHO statement addressing ethical concerns regarding the study design
News coverage of WHO criticism of US-funded newborn vaccine trial in Guinea-Bissau
Official trial registration information including funding sources and study design
Evidence Supporting the Claim
- CDC provided funding for a study examining hepatitis B vaccine administration timing in newborns in Guinea-Bissau
- The funding amount has been reported as approximately $1.6 million
- WHO Regional Office for Africa issued a statement expressing concerns about the ethical aspects of the study
- The study involves randomization of newborns regarding timing of hepatitis B vaccination
Evidence Against / Context
- The term 'slammed' represents editorial characterization rather than WHO's official language in their statement
- WHO's statement expressed concerns and requested review rather than categorically condemning the study
- The study appears to have undergone ethics review processes, though WHO raised questions about the adequacy of those reviews
- The ethical concerns center on study design and informed consent processes rather than all aspects of the research
Timeline
Reported scheduled completion date for the study
CDC awarded approximately $1.6 million grant for hepatitis B vaccine birth dose study in Guinea-Bissau
Study initiated in Guinea-Bissau examining timing of hepatitis B vaccination in newborns
WHO Regional Office for Africa issued statement expressing ethical concerns about the trial
What This Means
Structured interpretation — not opinion
Key takeaway 1
The CDC did fund a study in Guinea-Bissau related to hepatitis B vaccination in newborns, and WHO did express ethical concerns about it
Key takeaway 2
The characterization of WHO's response as 'slammed' represents interpretive framing of institutional criticism that may overstate the tone of official statements
Key takeaway 3
Ethical concerns in international research trials typically involve questions about informed consent, study design, and whether participants receive standard of care
Key takeaway 4
The funding amount of $1.6 million and WHO criticism are factually grounded, but the degree and nature of WHO's criticism requires examination of their actual statement language
Related Claims in health
“The FDA was changing leucovorin's label because it could help 'hundreds of thousands' of children with autism”
FDA Commissioner Marty Makary announced in September 2025 that the agency would change leucovorin's label to reflect potential benefits for some children with autism and cerebral folate deficiency. However, the FDA later clarified the label change applied to a rare subset of patients with a specific metabolic condition, not hundreds of thousands of children, and the agency disputed characterizations that overstated the scope of the change.
“The Trump administration enacted a 6-month moratorium on Minnesota Medicaid payments”
On February 27, 2026, the Trump administration implemented a six-month moratorium on federal Medicaid payments to Minnesota through the Centers for Medicare and Medicaid Services. The action was taken in response to Minnesota's policies regarding undocumented immigrants' access to state healthcare programs, which federal officials characterized as violations of federal law.
“90% of health care spending treats chronic disease”
The claim that 90% of healthcare spending treats chronic disease is an overstatement of the actual figures. Federal health agencies report that chronic diseases account for approximately 75-90% of healthcare spending, with the most commonly cited figure from the Centers for Disease Control and Prevention being 90% of the nation's $4.5 trillion in annual healthcare expenditures, though this appears to include broadly defined chronic conditions and may represent an upper-bound estimate.